By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: LENZ Therapeutics and Laboratoires Tha Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > LENZ Therapeutics and Laboratoires Tha Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
LENZ Therapeutics and Laboratoires Tha Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
Health

LENZ Therapeutics and Laboratoires Tha Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

GlobeNews Wire
Last updated: 07/07/2025 5:36 PM
GlobeNews Wire
Published: 07/07/2025
Share
SHARE

Exclusive agreement includes over $70 million in upfront and milestone payments to LENZ in addition to double-digit royalties on net sales

July 07, 2025 08:00 ET  | Source: LENZ Therapeutics, Inc.

SAN DIEGO and CLERMONT-FERRAND, France, July 07, 2025 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Laboratoires Théa (“Théa”) announced an exclusive license and commercialization agreement for Théa to register and commercialize LNZ100 for the treatment of presbyopia in Canada. LENZ Therapeutics is a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, which has a US FDA PDUFA date of August 8, 2025. Théa is an independent pharmaceutical company specialized in the research, development and commercialization of eye-care products.

Under the terms of the licensing and commercialization agreement, LENZ will be eligible to receive over $70 million in upfront, regulatory and commercial milestone payments, as well as tiered, double-digit royalties on net sales. Théa will have exclusive development, manufacturing, registration and commercialization rights for LNZ100 for the treatment of presbyopia in Canada.

“Théa is a leading company in eyecare in key markets around the world and was a natural choice for LENZ when looking for a highly capable commercial partner in Canada. With its strong position in commercializing eye drops, Théa is uniquely positioned to bring the benefits of LNZ100 to patients in this key market,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “This agreement represents our third commercialization partnership outside the United States for LNZ100, as we continue to be focused on maximizing patient access to this important therapy worldwide.”

Jean-Frédéric Chibret, President of Théa, commented: “Canada is an important part of Théa’s international development, and we have been active in the country for several years. Our local team plays an essential role in supporting both patients and eye care professionals. This partnership with LENZ will expand our portfolio with a promising therapy targeting a prevalent condition that affects millions of adults. We see strong potential for LNZ100 in Canada and look forward to initiating the registration process and making the treatment available to Canadian healthcare providers and their patients.

In October 2024, LENZ announced that the FDA accepted the NDA for LNZ100 for the treatment of presbyopia, a condition that impacts an estimated 1.8 billion people globally and 128 million people in the United States. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100, and noted it is not planning to hold an Advisory Committee Meeting to discuss this application.

About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.

About Théa
Théa is the leading independent European pharmaceutical company specializing in the research, development, and commercialization of ophthalmic products. Headquartered in Clermont-Ferrand, France, this family-owned company employs over 2,000 people and has built a strong international presence through a network of more than 35 independent subsidiaries and offices across Europe, North Africa, the Americas, and the Middle East. All products are manufactured in Europe—60% in France—and are available in 75 countries worldwide. In 2024, Théa reported revenues of €970 million. For more information, visit www.laboratoires-Théa.com or Laboratoires Théa : Présentation | LinkedIn

GACB Sathorn Experience Center & GAC Thailand Battery Service Center Officially Open
Risen Energy Launches Integrated Solar Storage Systems at SNEC 2025
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
Hycroft Announces Public Offering of Units
Kia Achieves Double Win at the 2025 Auto Express New Car Awards
TAGGED:agreementandannouncecanadacommercializationexclusiveforlaboratoireslenzlicenselnz100Nasdaq:LENZnewsthatherapeuticsUS52635N1037
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
DXC Opens Farnborough Office, Launches Aerospace and Defense Hub in the UK
News

DXC Opens Farnborough Office, Launches Aerospace and Defense Hub in the UK

27/06/2025
Elliott Calls for Further Action to Enhance Corporate Value and Strengthen Corporate Governance Ahead of Sumitomo Realty’s 2025 Annual General Meeting
BTCMiner: Ten Years of Safe and Stable Cloud Mining, Principal and Interest Guaranteed
KT&G Takes Legal Action Against Local Counterfeit Cigarette Manufacturers and Distributors in India
Maldives and Henley & Partners Sign Landmark Partnership Agreement to Launch Pioneering Residence by Investment Program
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?